RecruitingPhase 1NCT06515613
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Context Therapeutics Inc.
- Principal Investigator
- Karen Chagin, MDContext Therapeutics Inc.
- Intervention
- CTIM-76(drug)
- Enrollment
- 80 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (13)
- University of Arkansas Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
- Precision NextGen Oncology & Research Center, Beverly Hills, California, United States
- SCRI at Denver Health, Denver, Colorado, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- John Theurer Cancer Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Duke Cancer Institute, Durham, North Carolina, United States
- Gabrail Cancer Center, Canton, Ohio, United States
- Providence Cancer Institute of Oregon, Portland, Oregon, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- SCRI at Mary Crowley, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06515613 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT07544030A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancertongweihua